Zivo Bioscience EBIT

The latest EBIT for ZIVO is $-6.6M as of March 2026. That compares with $-16M in the prior-year period — up 59.4% year over year. That is below the Consumer Discretionary sector average of $140B. Investors often review this figure alongside Zivo Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, ZIVO's EBIT moved from $-16M to $-6.6M — a 59.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Zivo Bioscience's operating scale or balance-sheet position.

Against Consumer Discretionary companies, ZIVO currently prints $-6.6M for EBIT, while the sector average sits near $140B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Zivo Bioscience's growth, margins, and balance sheet.

A EBIT figure of $-6.6M for ZIVO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Consumer Discretionary average is about $140B. Explore the charts below for those layers of context.

After noting ZIVO's EBIT ($-6.6M), review year-over-year change from $-16M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.